- Home
- SLS vs ANIK Comparison
SLS vs ANIK Comparison
Compare SLS & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- ANIK
- Stock Information
- Founded
- SLS 2012
- ANIK 1983
- Country
- SLS United States
- ANIK United States
- Employees
- SLS N/A
- ANIK N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- ANIK Medical/Dental Instruments
- Sector
- SLS Health Care
- ANIK Health Care
- Exchange
- SLS Nasdaq
- ANIK Nasdaq
- Market Cap
- SLS 165.6M
- ANIK 157.8M
- IPO Year
- SLS N/A
- ANIK 1993
- Fundamental
- Price
- SLS $1.66
- ANIK $8.64
- Analyst Decision
- SLS Strong Buy
- ANIK Buy
- Analyst Count
- SLS 1
- ANIK 1
- Target Price
- SLS $7.00
- ANIK $15.00
- AVG Volume (30 Days)
- SLS 2.8M
- ANIK 156.3K
- Earning Date
- SLS 08-12-2025
- ANIK 07-30-2025
- Dividend Yield
- SLS N/A
- ANIK N/A
- EPS Growth
- SLS N/A
- ANIK N/A
- EPS
- SLS N/A
- ANIK N/A
- Revenue
- SLS N/A
- ANIK $114,548,000.00
- Revenue This Year
- SLS N/A
- ANIK N/A
- Revenue Next Year
- SLS N/A
- ANIK $9.70
- P/E Ratio
- SLS N/A
- ANIK N/A
- Revenue Growth
- SLS N/A
- ANIK 4.60
- 52 Week Low
- SLS $0.77
- ANIK $7.87
- 52 Week High
- SLS $2.27
- ANIK $27.50
- Technical
- Relative Strength Index (RSI)
- SLS 41.18
- ANIK 32.85
- Support Level
- SLS $1.75
- ANIK $7.87
- Resistance Level
- SLS $1.96
- ANIK $11.61
- Average True Range (ATR)
- SLS 0.12
- ANIK 0.67
- MACD
- SLS -0.04
- ANIK -0.29
- Stochastic Oscillator
- SLS 18.56
- ANIK 20.59
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.